



February 9, 2024

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code No: 542665	National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Company Symbol: NEOGEN
--	---

Dear Sir/Madam,

Sub: Disclosure under regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (“Listing Regulations”)

Ref.: SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019

Pursuant to Regulation 32 of Listing Regulations, we enclose herewith as **Annexure 1** the Statement of Deviation / Variation (“Statement”) as on December 31, 2023, duly reviewed by the Audit Committee at its meeting held on February 9, 2024.

We hereby confirm that there has been no deviation/ variation in the use of proceeds of funds raised through issue of Equity Shares on preferential basis.

This intimation is also being uploaded on the Company’s website at www.neogenchem.com and at the website of the National Stock Exchange of India Limited (www.nseindia.com) and BSE Limited (www.bseindia.com).

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you,
Yours faithfully,

For Neogen Chemicals Limited

Unnati Kanani
Company Secretary & Compliance Officer
Membership No: ACS 35131
Encl: A/a

Annexure 1

Quarterly Reporting for Preferential Issue of Equity Shares under Regulation 32 of Listing Regulation. Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity		Neogen Chemicals Limited				
SCRIP Code		542665				
NSE Symbol		NEOGEN				
MSEI Symbol		NOTLISTED				
ISIN		INE136S01016				
No. of times funds raised		1				
Mode of Fund Raising		Preferential Issue of Equity Shares				
Date of Raising Funds		01-11-2023				
Amount Raised (Rs. In crores)		253				
Report filed for Quarter ended		31-12-2023				
Monitoring Agency		Applicable				
Monitoring Agency Name, if applicable		CRISIL Ratings Limited				
Is there a Deviation / Variation in use of funds raised		NO				
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders		Not Applicable				
If Yes, Date of shareholder Approval		Not Applicable				
Explanation for the Deviation / Variation		Not Applicable				
Comments of the Audit Committee after review		No				
Comments of the auditors, if any		No				
Objects for which funds have been raised and where there has been a deviation, in the following table		See table below				
(Amount in Crores)						
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1. Investment in wholly owned subsidiaries of the Company viz. Neogen Ionics Limited and BuLi Chemicals India Private Limited.	NO	100	Not Applicable	100	0	Nil
2. Meeting Working capital requirements	NO	91		91	0	
3. General Corporate Purposes*	NO	62		62	0	*The amount utilized for general corporate purpose did not exceed 25% of the Gross proceeds.
		253		253	0	
Deviation or variation could mean:						
<i>(a) Deviation in the objects or purposes for which the funds have been raised or</i>						
<i>(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or</i>						
<i>(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc</i>						
Name of Signatory		Ketan Vyas				
Designation		Chief Financial Officer				
Date		09-02-2024				

